Immunocore announces strategic priorities including pipeline expansion for 2023 -2024
January 09, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 KIMMTRAK (tebentafusp-tebn) approved in over 30 countries with continued global expansion in 2023-2024;...
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq:...
Immunocore is awarded the Prix Galien France award for KIMMTRAK
December 15, 2022 06:00 ET
|
Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 08, 2022 06:30 ET
|
Immunocore Holdings Limited
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Phase 1 trial enrolled all comers, with vast majority of patients having zero or very low MAGE-A4...
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
December 02, 2022 07:30 ET
|
Immunocore Holdings Limited
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors Gamma delta TCRs offer potential to address large number of patients without HLA restrictions ...
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
November 11, 2022 09:00 ET
|
Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
Immunocore to present at the Jefferies London Healthcare Conference
November 10, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR),...
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update Net KIMMTRAK / tebentafusp revenues of £36.3 million ($40.4 million) in Q3 2022 Promising clinical activity...
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
September 09, 2022 10:00 ET
|
Immunocore Holdings Limited
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial shows IMC-F106C, a PRAME×CD3...